OPEN Health mobilised to support outcomes with gene and other advanced therapies

Written by Gavin Jones on Wednesday 30th October 2019

Harnessing the power of collaborations to bring real insights and improve outcomes 

The imminent explosion of gene and other advanced therapies brings with it a lot of hope and expectation along with unprecedented challenges faced by bio-pharma - big and small. 

The power of the rare disease community has to be harnessed to get these potentially life changing treatments into health systems and to patients in a timely and sustainable fashion. 

These are rapidly evolving and exciting times where everyone is learning together and collaboration is key to ensure best practice and novel approaches see widespread adoption. 

OPEN Health brought together our existing knowledge in the space to develop experience based thinking on the topics of creating insight and value for gene and other advanced therapies. In addition OPEN Health always values opinion leaders in a particular field and were therefore delighted to be able to interview Nicki Redfern from bluebird bio to hear about their progress and the evolving landscape. 

Finally we focus on what we see as a key challenge that requires a new approach. This is how do you deliver effective and sustained outcomes monitoring following initiation of one of these innovative therapies. Read our thinking in this space here.

Pink divider

Get in touch

For more information contact Gavin Jones | Director of Rare Disease | OPEN Health
GavinJones@OpenHealthGroup.com

+44 (0) 7795 038952